| Literature DB >> 35736145 |
Hossam S El-Beltagi1,2, Amal A Mohamed3,4, Heba I Mohamed5, Khaled M A Ramadan6,7, Aminah A Barqawi3, Abdallah Tageldein Mansour8,9.
Abstract
Since ancient times, seaweeds have been employed as source of highly bioactive secondary metabolites that could act as key medicinal components. Furthermore, research into the biological activity of certain seaweed compounds has progressed significantly, with an emphasis on their composition and application for human and animal nutrition. Seaweeds have many uses: they are consumed as fodder, and have been used in medicines, cosmetics, energy, fertilizers, and industrial agar and alginate biosynthesis. The beneficial effects of seaweed are mostly due to the presence of minerals, vitamins, phenols, polysaccharides, and sterols, as well as several other bioactive compounds. These compounds seem to have antioxidant, anti-inflammatory, anti-cancer, antimicrobial, and anti-diabetic activities. Recent advances and limitations for seaweed bioactive as a nutraceutical in terms of bioavailability are explored in order to better comprehend their therapeutic development. To further understand the mechanism of action of seaweed chemicals, more research is needed as is an investigation into their potential usage in pharmaceutical companies and other applications, with the ultimate objective of developing sustainable and healthier products. The objective of this review is to collect information about the role of seaweeds on nutritional, pharmacological, industrial, and biochemical applications, as well as their impact on human health.Entities:
Keywords: antioxidant activity; functional foods; health benefits; seaweeds; secondary metabolites
Mesh:
Substances:
Year: 2022 PMID: 35736145 PMCID: PMC9227187 DOI: 10.3390/md20060342
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Three example species of brown (a) red (b) and green (c) seaweeds. Adapted from ref. [14] obtained from mdpi journals.
Figure 2Main bioactive compounds from marine seaweeds.
Figure 3Chemical structures of different types of polysaccharides in seaweeds.
Seaweeds polysaccharides and their roles in medicine.
| Component | Species | Molecular Weight | Chemical Composition | Doses | Properties/Activities | References |
|---|---|---|---|---|---|---|
| Carrageenan |
| 197 kDa | Heteropolysaccharide composed mainly of galactose | 250 μg mL−1 | Anticancer activity | [ |
| Porphyran |
| f 9.7–34.6 kDa | Mainly composed of 3,6-anhydro-L-galactose | 327.3 μg mL−1 | Anticancer activity | [ |
| Fucoidans |
| 75.0 kDa | 5.01 mg mL−1 of l-fucose, 2.02 mg mL−1 of uronic acids and 1.65 ppm of sulfate | 1 mg mL−1 | Anticancer activities | [ |
|
| - | Fucose and Xylose | - | Antioxidant activity | [ | |
| Agar |
| 1.21 × 104 Da and 1.85 × 105 Da | (1–4)-linked 3,6-anhydro-α-L-galactose alternating with (1–3)-linked β-D-galactopyranose | 25.6 mg L−1 | Antioxidant activity | [ |
| Laminaran |
| - | β-(1,3)-glucan | 10 µg mL−1 | Antioxidant protection | [ |
| Ulvan |
| 83.1 from 143.2 kDa | Rhamnose, and xylose | 500 mg kg−1 | Antioxidant and antihyperlipidemic activity | [ |
| 143.47 kDa | Rhamnose and xylose | 1.5 mg mL−1 | Antioxidant Activity | [ |
Seaweeds polysaccharides and their roles in foods and cosmeceuticals.
| Component | Species | Models | Doses | MW | Activity | Results | References |
|---|---|---|---|---|---|---|---|
| Carrageenan |
| Paw edema in rats | 20 mg kg−1 | 25 kDa | Anti-inflammation | COX-2 and iNOS inhibitions | [ |
| Fucoidan |
| Human malignant | 100–400 µg mL−1 | 60 kDa | Anticancer activity | Inhibit cell proliferation | [ |
| B16 murine melanoma | 550 µg mL−1 | - | Anti-melanogenic | Inhibit tyrosinase and melanin | [ | ||
| Ulvans |
| 100 and 500 µg mL−1 | 4–57 kDa | Anti-aging | Increase hyaluronan production | [ | |
| Laminaran |
| In vitro | 15 mg mL−1 | 250 kDa | antioxidant | ROS scavenging potential | [ |
| Fucoidan |
| RAW macrophages | 27.82 µg mL−1 | 60 kDa | Anti-inflammation | Inhibition of LPS-induced NO | [ |
| Fucoidan |
| RAW 264.7 macrophage | dose-dependent manner | - | Anti-inflammation | Inhibit LPS-induced inflammatory | [ |
| Fucoidan |
| B16 melanoma cells | dose-dependent manner | - | Anticancer | Activation of caspase-3 | [ |
Different proteins accumulation of some seaweeds.
| Seaweed | Species | Name of the Protein | Protein Yield % | References |
|---|---|---|---|---|
| Green algae | Glycoproteins (GP) | “UvGP-1” (0.54) “UvGP-2 DA”(0.52) “UvGP-2-DS”(1.98) | [ | |
|
| Green algae | GP fraction G | ND | [ |
|
| Brown algae | Glycoprotein | 0.27 | [ |
|
| Red algae | Lectins “SfL-1” “SfL-2” | ND | [ |
|
| Red algae | Lectin “SfL” | ND | [ |
|
| Green algae | “Cf-hGP” | ND | [ |
|
| Brown algae | “UPGP” | ND | [ |
ND: Not detected; SfL: Solieria filiformis lectin; Cf-hGP: Capsosiphon fulvescens hydrophilic glycoproteins; UPGP: Undaria pinnatifida glycoprotein.
Amino acid composition accumulation of some seaweeds (g amino acid 100 g−1 protein).
| No. | Amino Acids (AA) | ||||||
|---|---|---|---|---|---|---|---|
| Essential AA | |||||||
| 1 | Threonine | 6.38 | 5.41 | 2.49 | 2.25 | 0.15 | 5.84 |
| 2 | Valine | 7.03 | 6.30 | 2.49 | 2.20 | 0.23 | 9.97 |
| 3 | Lysine | 6.63 | 6.02 | 1.51 | - | 0.20 | 4.22 |
| 4 | Isoleucine | 5.01 | 4.23 | 2.14 | 1.98 | 0.18 | 8.05 |
| 5 | Leucine | 8.00 | 7.90 | 2.34 | 2.16 | 0.26 | 15.88 |
| 6 | Phenylalanine | 4.93 | 5.26 | 2.11 | 1.79 | 0.19 | 9.97 |
| 7 | Methionine | - | - | 1.69 | 1.61 | 0.05 | 3.89 |
| Non essential AA | |||||||
| 8 | Aspartic | 11.56 | 12.50 | 3.33 | - | 0.53 | 4.17 |
| 9 | Serine | 6.14 | 6.39 | 2.68 | 2.90 | 0.10 | 5.38 |
| 10 | Glutamic | 14.39 | 12.98 | 11.67 | 2.79 | 0.58 | 17.87 |
| 11 | Glycine | 6.87 | 6.49 | 2.97 | 2.18 | 0.22 | 18.36 |
| 12 | Arginine | 7.03 | 8.65 | 2.40 | 2.40 | 0.19 | 4.83 |
| 13 | Histidine | 0.65 | 1.08 | 1.60 | 2.29 | 0.07 | 2.26 |
| 14 | Alanine | 6.87 | 8.09 | 2.93 | 2.51 | 0.23 | 9.57 |
| 15 | Tyrosine | 3.88 | 3.62 | 1.81 | 1.74 | 0.05 | 4.45 |
| 16 | Proline | 4.61 | 5.08 | - | - | 0.17 | 7.95 |
| 17 | Cystin | - | - | - | - | 0.00 | 0.78 |
Seaweeds proteins and their roles in medicinal.
| Component | Properties/Activities | Seaweed | Doses | Molecular Weight | References |
|---|---|---|---|---|---|
| Peptide PPY1 | Anti-aging |
| 250–1000 ng mL−1 | 532 Da | [ |
| Peptides PYP1-5 and porphyra 334 | Boost synthesis of elastin | 0–200 μM | 1622 kDa | [ | |
| Lactate and progerin | Reduce synthesis, |
| - | 112 KDa | [ |
| Phycobiliproteins | Antioxidant |
| 0.5–30 mg mL−1 | 240 KDa | [ |
| Deoxygadusol, palythene and usujirene | Antioxidant |
| - | - | [ |
| Palythine, palythinol, porphyra-334, asterina-330, shinorine, or usujirene | Antioxidant, antiproliferative | 2.0–4.0 mg mL−1 | 244.24 KDa | [ | |
| Porphyra-334, shinorine, palythine and asterina-330 | Antioxidant; UV-protective effect |
| - | 346.33 KDa | [ |
Lipids accumulation of some seaweeds.
| Seaweed | Species | Lipids g/100 g | EPA (%) | DHA (%) | References |
|---|---|---|---|---|---|
|
| Green algae | 1.11 ± 0.05 | 0.86 | - | [ |
|
| Green algae | 1.5 ± 0.0 | 2.10 ± 0.00 | - | [ |
|
| Green algae | 1.27 ± 0.11 | 0.87 ± 0.16 | 0.8 ± 0.01 | [ |
|
| Red algae | 1.3 ± 0.0 | 1.3 ± 0.01 | - | [ |
| Red algae | 1.0 ± 0.2 | 10.4 ± 7.46 | - | [ | |
|
| Brown algae | 3.62 ± 0.17 | 7.24 ± 0.08 | - | [ |
|
| Brown algae | 6.54 ± 0.27 | 4.09 ± 0.08 | 11.10 ± 1.13 | [ |
|
| Brown algae | 0.8 ± 0.1 | 4.95 ± 0.11 | 1.66 ± 0.02 | [ |
|
| Brown algae | 3.75 ± 0.20 | 9.94 ± 0.14 | - | [ |
|
| Brown algae | <1.5 | 7.45 | - | [ |
| Brown algae | 1.0 ± 0.3 | 16.2 ± 8.9 | - | [ | |
|
| Brown algae | 0.7 ± 0.1 | 0.47 ± 0.01 | - | [ |
|
| Brown algae | 1.4 ± 0.1 | 42.4 ± 11.9 | - | [ |
|
| Brown algae | 4.5 ± 0.7 | 413.2 ± 0.66 | - | [ |
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
The seaweeds lipids and their apllications.
| Component | Molecular Mass | Properties/Activities | Seaweed | References |
|---|---|---|---|---|
| E-9-oxooctadec-10-enoic acid E-10-oxooctadec-8-enoic acid | 282.46 g mol−1 | Anti-inflammatory |
| [ |
| Essential oil (tetradeconoic acid, hexadecanoic acid, (9Z)-hexadec-9-enoic acid) | 280.447 g mol−1 | Antioxidant: radical scavenging |
| [ |
| Fucosterol | 412.69 g mol−1 | Antioxidant: increased antioxidative enzymes (glutathione peroxidase, superoxide dismutase, catalase) |
| [ |
| Fucosterol | 412.69 g mol−1 | Anti-inflammatory, Ati-photodamage: decreased UVB-induced MMPs |
| [ |
| Palmitic acid | 256.430 g mol−1 | Enzyme inhibition, Antioxidant | [ | |
| Omega 3 fatty acids | 909.4 g mol−1 | Antioxidant | Brown algae | [ |
| Arachidonic acid (ARA) | - | Improves growth and development of neonates | [ | |
| Eicosapentaenoic | 500 mg/day | Cognition, heart health, protection against | [ | |
| Docosahexaenoic | 500 mg/day | Brain and eye health, cardiovascular | [ | |
| Fucosterol | 1 and 10 μg mL−1 | Anti-aging |
| [ |
| Polyunsaturated fatty acid | 10.3 mg mL−1 | Anti-inflammation |
| [ |
Figure 4Chemical structures of different types of pigments in seaweeds.
Summarizes the key activities of carotenoids in human health.
| Carotenoid | Seaweed Source | Effect | Model | Bioactive Concentration | Target | Reference |
|---|---|---|---|---|---|---|
| Astaxanthin |
| Antioxidant | Human monocytes (U-937) | 10 μM | SHP-1 | [ |
| Mice brain | 2 mg/kg/day | MDA, NO, APOP, GSH. | [ | |||
| Leydig cells | 10 μg/mL | StAR | [ | |||
| Antiproliferative | human prostatic adenocarcinoma (LNCaP) | 10 μM | prostate specific antigen (PSA) | [ | ||
| immune system stimulation | transplantable methylcholanthrene-induced fibrosarcoma (Meth-A tumor) | 40 mg/kg/day | interferon-g (IFN-γ) | [ | ||
| anti-obesity | Humans | 0, 6, 12 and 18 mg/day | adiponectin | [ | ||
| Cardiovascular protective | spontaneously hypertensive rats (SHR) | 50 mg/kg | blood pressure (BP) | [ | ||
| Fucoxanthin |
| antioxidant and protective | Vero cells | 5, 50, 100 and 200 µM (50 µM H2O2) | DNA | [ |
| UV protection | Human fibroblasts | 5, 50 and 100 µM (50 mJ/cm2 UV-B) | DNA | [ | ||
| Antioxidant | Retinol deficiency rats | 0.83 µM | CAT, GST and Na+K+ATPase activity | [ | ||
| Antiproliferative | leukemia cells (HD-60) | 11.3 and 45.2 μM | DNA fragmentation | [ | ||
| colorectal adenocarcinoma cells (Caco-2) | 15.2 μM | DNA fragmentation | [ | |||
| colorectal adenocarcinoma cells (DLD-1) | 15.2 μM | DNA fragmentation | [ | |||
| colorectal adenocarcinoma cells (CHT-29) | 15.2 μM | DNA fragmentation | [ | |||
| human colorectal carcinoma (HCT116) | 5 and 10 μM | Bcl-xL, PARP and caspase 3 and 7 | [ | |||
| Antiproliferative | human urinary bladder cancer cells (EJ-1) | 20 μM | [ | |||
| anti-obesity | Rats | 2 mg | absorption of triglycerides, pancreatic lipase | [ | ||
| Fucoxanthinol |
| Antiproliferative | human prostate cancer (PC-3) | 2.0 μM | Bcl-xL, PARP and caspase 3 and 7 | [ |
| anti-obesity | Rats | 2 mg | absorption of triglycerides, pancreatic lipase | [ | ||
| Halocynthiaxanthin |
| Antiproliferative | human neuroblastoma cells (GOTO) | 5 μg/mL | [ | |
| β-carotene |
| Antioxidant | Smokers | 20 mg | Breath pentane | [ |
| Cure of erythema | Humans | 30 to 90 mg/day | [ | |||
| Antiproliferative | murine osteosarcoma (LM8) | 30 µM | [ | |||
| Antiinfiammatory | human umbilical vein endothelial cells (HUVECs) | 0.02 µmol/L | VCAM-1, ICAM-1 and E-Selectin | [ | ||
| Lutein |
| ADM prevention | Human Dermal Lymphatic Endothelial Cells (HLEC) | 5 µM | DNA, lipid and protein level | [ |
| Cardiovascular protective | Human monocytes | 0.1, 1, 10 and 100 nM | LDL associated with artery wall | [ | ||
| Zeaxanthin |
| ADM prevention | Human Dermal Lymphatic Endothelial Cells (HLEC) | 5 µM | DNA, lipid and protein level | [ |
Abbreviations: SHP-1: protein tyrosine phosphatase non-receptor type 6; MDA: Malondialdehyde; NO: nitric oxide; APOP: protein oxidation product; GSH: glutathione; CAT: catalase; GST: glutathione S-transeferase; Bcl-xL: antiapoptotic factor; PARP: poly-ADP-ribose polymerase; (VCAM-1, ICAM-1): genes coding for vascular adhesion proteins.
Figure 5Several seaweeds synthesize phenolic substances. Adapted from ref [194] obtained from mdpi journals. (A)—Ascophyllum nodosum (P); (B)—Bifurcaria bifurcata (P); (C)—Fucus vesiculosus (P); (D)—Leathesia marina (P); (E)—Lobophora variegata (P); (F)—Macrocystis pyrifera (P); (G)—Asparagopsis armata (R); (H)—Chondrus crispus (R); (I)—Gracilaria sp. (R); (J)—Kappaphycus alvarezii (R); (K)—Neopyropia sp. (R); (L)—Palmaria palmata (R); (M)—Dasycladus vermicularis (Chl); (N)—Derbesia tenuissima (Chl); (O)—Ulva intestinalis (Chl); P—Phaeophyceae, R—Rhodophyta; Chl—Chlorophyta.
Figure 6Chemical structures of different types of phenols in seaweeds.
Figure 7Damage caused via reactive oxygen species (ROS). Adapted from ref. [233] obtained from mdpi journals.
Figure 8Reactive oxygen species and neutralization by several biomolecules.
Figure 9Demonstrate the ability of algal polysaccharide (SP)-based customized signals produced from sea algae to cause tumor cell death (apoptosis). Adapted from ref. [233] obtained from mdpi journals.
Bioactive compounds derived from algae and their applications.
| Algae Species | Bioactive | Beneficial Activity | Mechanism of Action | Experimental Model | Reference |
|---|---|---|---|---|---|
|
| |||||
|
| Ascophyllan | Anticancer | Inhibit MMP expression | B16 melanoma cells | [ |
|
| Eleganonal | Antioxidant | DPPH inhibition | In vitro | [ |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Fucoidan | Anti-inflammation | Inhibition of LPS-induced NO production, iNOS, COX-2, and PGE2 levels | RAW macrophages | [ |
|
| Fucoxanthin | Antioxidant | DPPH inhibition | In vitro | [ |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Fat-soluble vitamin and carotenoids | Antioxidant | High fat-soluble vitamin and | In vitro | [ |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Algae extract | Antimicrobial | Inhibit the synthesis of the | [ | |
|
| Phlorotannin | Anti-inflammation | Inhibit release of histamine | Rat basophile leukemia | [ |
|
| Fucoidan | Anticancer | Inhibit cell proliferation | Human malignant | [ |
|
| Ethanol extract | Anti-inflammation | COX-2 inhibition | COX inhibitory screening | [ |
|
| Fucoxanthin | Anti-melanogenic | Suppress tyrosinase activity | UVB-irradiated guinea pig | [ |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Phenol | Antioxidant | High total phenolic content, DPPH scavenging activity and FRAP | In vitro | [ |
|
| |||||
|
| Methanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Methanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Glycosaminoglycan | Anti-aging | Collagen synthesis | Unknown | [ |
|
| Sesquiterpenes | Antimicrobial | Bacterial growth inhibition |
| [ |
|
| Methanol extract | Antioxidant | β-carotene bleaching activity | In vitro | [ |
|
| Sulfated Polysaccharide | Antioxidant | ROS scavenging potential | Mice | [ |
|
| Phenol | Anti-melanogenic | Inhibit tyrosinase activity | In vitro | [ |
|
| |||||
|
| Polysaccharide | Antioxidant | ROS scavenging potential | In vitro | [ |
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | ||
|
| Chloroform and methanol extract | Antioxidant | SOD activity is reduced |
| [ |
|
| Fucoxanthin | Antioxidant | High FRAP value | In vitro | [ |
|
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | |
|
| Fucoxanthin | Antioxidant | DPPH inhibition (83.95%) | In vitro | [ |
|
| Polysaccharide | Antioxidant | ROS scavenging potential | In vitro | [ |
|
| |||||
|
| Lycopene | Antioxidant | N/A | In vitro | [ |
|
| Methanol extracts of | Antioxidant | N/A | In vitro | [ |
|
| Sporopollenin | Anti-aging | Protect cells from UV radiation | N/A | [ |
|
| MAA | Anti-aging | Protect cells from UV radiation | N/A | [ |
|
| MAA | Anti-aging | Protect cells from UV radiation | N/A | [ |
| Lutein | Anti-aging | Reduce UV induced damage | N/A | [ | |
|
| Hot water extract | Anti-aging | Reduced activity of SOD | Human diploid fibroblast | [ |
| Anti-inflammation | Down-regulated mRNA expression | NC/Nga mice | [ | ||
|
| β-carotene | Antioxidant | Protect against oxidative stress | Rat | [ |
| β-cryptoxanthin | Anti-inflammation | Reduced the production of IL-1β, | LPS-stimulated RAW | [ | |
|
| Astaxanthin (carotenoid) | Anti-aging | Inhibit MMP expression | Mice and human dermal | [ |
| Anticancer | ROS scavenging potential | Mice | [ | ||
|
| Carotenoid | Antioxidant | DPPH inhibition | In vitro | [ |
|
| Zeaxanthin | Anti-melanogenic | Inhibit tyrosinase | In vitro | [ |
| Fucoxanthin | Antioxidant | Reduced oxidative stress | Human Glioma Cells | [ | |
| MAA | Antioxidant | ROS scavenging potential | In vitro | [ | |
|
| EPA | Antioxidant | Reduce oxidative stress | Rat | [ |
|
| Fatty acid | Antimicrobial | Bacterial growth inhibition | [ | |
| Sulfated polysaccharide | Anti-inflammation | Inhibit proinflammatory modulator | Unknown | [ | |
|
| Sulfated polysaccharide | Antioxidant | ROS scavenging potential | In vitro | [ |
|
| Polyunsaturated aldehyde and fatty acid | Anticancer | Inhibit cell proliferation | Human melanoma cells | [ |
|
| β-carotene and | Antioxidant | Inhibit lipid peroxidation Inhibit TNF-ɑ and IL-6 expressions | Mouse Human dermal fibroblast cells (CCD-986sk) | [ |
| Ethanol extract | Antimicrobial | Bacterial growth inhibition | [ | ||
| Fatty acids and phenols | Antimicrobial | Bacterial growth inhibition | [ | ||
Figure 10Illustration demonstrating beneficial effects of seaweed extracts on the entire soil-plant system. Such impacts include increased fruit quality and phytohormone content in plants, increased soil enzymatic activity, improved roots system, and overall physiological properties of plants. Adapted from ref. [315] obtained from mdpi journals.
Biomedical effects of seaweed bioactive compounds.
| Seaweed | Compound | Cell Lines/Animals | Route of | Dosage (μg/mL) | Effect | Reference |
|---|---|---|---|---|---|---|
| Sulfated fucan | Human plasma | The lyophilized | 10, 30, 50 | In vitro | [ | |
| Fucoidans | Human plasma | Intravenous | 125, 250, 500, 1000 | In vitro and | [ | |
| Phenolic, Flavonoid and | Bovine serum | The extracts were | 20, 40, 60, 80, 100, | Hypoglycemic | [ | |
| Phlorotannins, grasshopper | Mice | Oral | Based on weight of | Antioxidant, | [ | |
| Griffithsin (protein) | MERS-CoV and | The extracts were | 0.125, 0.25, 0.5, 1, 2 | Antiviral activity | [ | |
| Ethanolic extract | Twenty-four male | Oral | 500 mL of water | In vivo antihyperglycaemic, | [ | |
| polysaccharides | SARS-CoV-2 S-protein | The extracts were | 50–500 | In vitro inhibition | [ |
The potential pharmacological activity of brown, red and green seaweeds.
| Component | Properties/Activities | Seaweed | Doses | Models | References |
|---|---|---|---|---|---|
| Fucoxanthins | Antitumoral activity on lung |
| 12.5–100 μM | Female and male (1:1 ratio) BALB/c nude mice (18–20 g; 6–8 weeks of age) | [ |
| Antitumoral activity on MCF-7, HepG-2, HCT-116 cells | 100 and 200 mg/kg | Paracetamol-administered rats (one dose of 1 g/kg) | [ | ||
| Antitumoral activity on SiHa, Malme-3M cells |
| 1.5625, 6.25, 12.5, 25, 50, 80, 100 µM | Human cell lines | [ | |
| Antimicrobial activity |
| 2–2000 µg/mL. |
| [ | |
| Antimicrobial activity |
| 2, 3, 4, 5, 6, 7, and 7.5 mg/mL | [ | ||
| Antimicrobial activity |
| 2, 4, 6, 8 and 10 mg/mL | [ | ||
| Antiviral activity against ECHO-1, HIV-1, HSV-1, HSV-2 |
| 200 μg/mL | Female outbred mice (16–20 g) | [ | |
| Sulfate polysaccharide | Antiviral activity against |
| 0.78–12.5 μg/mL | Vero cells (African green monkey kidney cell line) | [ |
| Anti-obesity, antidiabetic activities |
| 5–10% Seaweed powder | Dawley laboratory rats (4 to 5 months old, 250–300 g) | [ | |
| Phloroglucinol | Anti-inflammatory activity |
| 1, 5, 10, 50 | HT1080 and | [ |
Figure 11A summary for the bioactive compounds that have different biological activities and used in different applications. Adapted from ref. [384] obtained from mdpi journals.